-
BML-277: A Practical Chk2 Inhibitor Workflow
2026-09-15
BML-277 combines nanomolar biochemical Chk2 inhibition with a cellular use case in radiation-induced apoptosis inhibition. This guide translates the compound into reproducible kinase, T-cell, and DNA damage response research workflows while separating established evidence from forward-looking applications.
-
Indazole/Indole Glucagon Receptor Antagonists
2026-09-15
The reference study describes a novel indazole- and indole-based series of glucagon receptor antagonists derived from the MK-0893 lead and maps activity across several core positions. Its most important translational result was oral activity for compound 16d in acute glucagon-challenge and diabetic mouse models, while the synthetic route illustrates how HOBt-assisted amide bond formation can support medicinal chemistry diversification.
-
Tigecycline Workflows for MDR Bacteria
2026-09-14
Tigecycline is a glycylcycline antibiotic that links ribosomal mechanism studies with practical susceptibility, time-kill, and resistance-transmission workflows. This guide shows how to use it as a phenotypic comparator in multidrug-resistant bacteria research while avoiding common interpretation, solubility, and assay-design errors.
-
NAD+: Mechanism, Evidence, and Lab Workflow
2026-09-14
Nicotinamide Adenine Dinucleotide (NAD+) is a redox coenzyme and substrate for enzymes that regulate DNA damage responses, protein deacetylation, and cellular stress signaling. This evidence-focused guide explains NAD+ chemistry, product handling for SKU B1793, and the limits of connecting NAD+ biology with caspase-dependent stress adaptation.
-
BCL-2 Targeting Across Heterogeneous CRPC
2026-09-13
This study combines single-cell imaging, mechanistic experiments, therapeutic models, and a Phase Ib trial to identify BCL-2 as a shared vulnerability across heterogeneous castration-resistant prostate cancer. Its findings show that androgen receptor pathway inhibition can increase BCL-2-positive populations, supporting treatment strategies that address both AR-positive and AR-low disease states.
-
JHU-083 Workflow for Glutaminase Research
2026-09-12
JHU-083 enables cell-focused interrogation of glutaminase activity, glutamate handling, and excitotoxicity-related phenotypes in neurological models. This workflow pairs its cerebral CD11b-cell use case with redox and multi-omics readouts inspired by recent hepatotoxicity research, while clearly separating validated product facts from assay-development recommendations.
-
Reversine Workflows for Aurora Kinase Research
2026-09-12
Reversine provides a practical way to interrogate Aurora kinase signaling, mitotic checkpoint failure, and treatment-associated cell death in cancer models. Its use can also be extended experimentally to indexed gastruloid arrays, where single-structure imaging and sorting help reveal heterogeneous responses that bulk assays may miss.
-
Rotavirus Infection Suppresses Nrf2 Redox Defense
2026-09-11
This study shows that rotavirus infection produces a biphasic Nrf2 response: an early, antioxidant-sensitive increase is followed by progressive loss of Nrf2, nuclear depletion, and reduced expression of cytoprotective genes. Its main innovation is the evidence that late Nrf2 depletion is not rescued by simply slowing canonical Keap1/Cul3-mediated turnover but is associated with proteasome-sensitive, K48-linked ubiquitination.
-
Metoprolol Workflows for Cardiovascular and Cell Research
2026-09-11
Build reproducible Metoprolol assays by pairing beta1-receptor pharmacology with disciplined exposure control, matrix-aware validation, and orthogonal readouts. The workflow also shows how the compound can support exploratory inflammation, cancer, and angiogenesis studies without confusing exploratory phenotypes with receptor-specific evidence.
-
Cardiac Biomarkers in Epileptic Baboons
2026-09-10
Szabó and colleagues used simultaneous scalp EEG and ECG recordings in a pedigreed baboon population to identify cardiac features associated with epilepsy. The study found significant QT and QTcF prolongation, while reduced HRV was suggestive but not statistically significant, supporting a natural model for investigating SUDEP-related physiology.
-
SIRT1/2 Inhibitor IV (cambinol) Assay Guide
2026-09-10
Learn how to use SIRT1/2 Inhibitor IV (cambinol) to interrogate SIRT1-regulated lactylation, STAT3 transport, p53 acetylation, tubulin biology, and tumor responses. This workflow separates established product evidence from practical assay extensions, helping researchers design stronger CNS, cancer, and metabolic studies.
-
SmD2 Acetylation Links Splicing to PARP Response in HCC
2026-09-09
This study identifies SmD2 as an acetylation-sensitive core spliceosome component that connects alternative splicing with DNA-damage repair and PARP-inhibitor response in hepatocellular carcinoma. Its findings support a combination strategy involving HDAC2-directed regulation and PARP inhibition, while also highlighting the need for careful validation before extending the mechanism to other HDAC inhibitors or tumor types.
-
ABT-263 (Navitoclax): Translational Apoptosis Strategy
2026-09-09
A mechanistic guide to using ABT-263 (Navitoclax) in cancer biology, apoptosis assays, and translational model selection, with practical validation strategies and a careful comparison to senolytic research in expanded chondrocytes.
-
Lumiracoxib: Timing COX-2 in Muscle Repair
2026-09-08
Lumiracoxib is a selective COX-2 inhibitor that can reveal how inflammatory prostaglandin signaling changes across muscle injury and revascularization. This article translates time-resolved findings into practical assay decisions, formulation guidance, and interpretation safeguards.
-
Miltefosine Activates ERK to Restore Neutrophils
2026-09-08
A 2025 study identifies Miltefosine as a candidate intervention for leukopenia by promoting neutrophil differentiation through the Ras/MEK/ERK cascade. Using leukemia-cell models, an irradiation-induced mouse model, transcriptomics, network pharmacology, docking, and pathway inhibition, the authors connect this response to improved myelopoiesis and neutrophil function.